...+ Ireland-based Perrigo Co. plc has announced a profit warning due to tougher competition in its generic prescription (Rx) business and further weakness in its recently acquired European branded consumer health care business. + The weaker-than-expected profits have led us to revise downward our projections, and we now expect the company's financial leverage will remain elevated over the forecast period. + As a result, we are lowering all of our ratings on the company, including our corporate credit rating to '###-' from '###'. + The stable outlook reflects our expectation for EBITDA to weaken by about 10% in 2016 on a pro forma basis, which leads to a debt-to-EBITDA ratio around the mid-3x area. CHICAGO (Standard & Poor's) April 26, 2016--Standard & Poor's Ratings Services today lowered all of its ratings on Dublin-based Perrigo Co. plc, including the corporate credit rating to '###-' from '###'. The outlook is stable. Reported debt outstanding as of Dec. 31, 2015 was about $6 billion....
